Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Nancy Snyderman
AddedFeb 19, 2024
UpdatedMay 31, 2026
Nancy Snyderman

Nancy Snyderman

Board Member, Axonics

LinkedInThe Org

Nancy Snyderman's Career

Axonics
Axonics

Irvine, CA, US

Board Member· Board
Lyra Therapeutics
Lyra Therapeutics

Watertown, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Nancy Snyderman's Career

Axonics
Axonics
Public6102012Irvine, CA, US
Board Member· Board

Leadership at Axonics

Dan L. DearenDan L. DearenFounder
Esteban López, MD, MBAEsteban López, MD, MBABoard Member
Raymond W. CohenRaymond W. CohenBoard Member
Mike CarrelMike CarrelBoard Member
Dave DemskiDave DemskiBoard Member
Lyra Therapeutics
Lyra Therapeutics
Public$264.1M662014Watertown, MA, US
Board Member· Board

Leadership at Lyra Therapeutics

George WhitesidesGeorge WhitesidesCo-Founder
Paulina HillPaulina HillBoard Member
Bob LangerBob LangerBoard Member
Guido NeelsGuido NeelsBoard Member
Konstantin PoukalovKonstantin PoukalovBoard Member
Maria BerkmanMaria BerkmanBoard Member

Similar to Lyra Therapeutics

LyndraLyndraWatertown, MA, USPharmaceuticals, Therapiesest. 2015LyndraWatertown, MA, US · est. 2015

US-based Lyndra Therapeutics develops therapies for Alzheimer's, HIV, opioid use disorder, and schizophrenia.

Series E · $284.6M161
Lyric PharmaceuticalsLyric PharmaceuticalsSan Francisco, CA, USTherapeuticsest. 2013Lyric PharmaceuticalsSan Francisco, CA, US · est. 2013

Lyric, a clinical-stage company, innovates gastrointestinal therapeutics for unmet hospital needs.

Series A · $20.4M6
Cara TherapeuticsCara TherapeuticsStamford, CT, USDrugs, Therapeuticsest. 2004Cara TherapeuticsStamford, CT, US · est. 2004

Cara Therapeutics, a Connecticut-based medical firm, develops novel drugs for pain and inflammation treatment.

Public · $517.2M106
Cyrano TherapeuticsCyrano TherapeuticsDelray Beach, FL, USPharmaceuticals, Therapeuticsest. 2014Cyrano TherapeuticsDelray Beach, FL, US · est. 2014

Cyrano Therapeutics: Innovating intranasal solutions to restore taste and smell functions.

Series B · $21.8M7

Nancy Snyderman's Similar Executives & Operators

WILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · KakaoBrian KimBrian KimBoard Member · KakaoHong EuntaekHong EuntaekBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Nancy Snyderman

Larry BrilliantLarry BrilliantBoard Member · SalesforceLouis AronneLouis AronneCo-Founder · IntellihealthDavid AgusDavid AgusBoard Member · Thrive GlobalPaul StoffelsPaul StoffelsBoard Member · PhilipsSteven QuaySteven QuayBoard Member · Atossa TherapeuticsCharity DeanCharity DeanBoard Member · The Public Health Company